TY - JOUR
T1 - Fraction of exhaled nitric oxide is higher in liver transplant recipients than in controls from the general population
T2 - a cohort study
AU - Arentoft, Nicoline S.
AU - Fialla, Annette D.
AU - Krohn, Paul S.
AU - Patursson, Magda T.
AU - Thudium, Rebekka F.
AU - Suarez-Zdunek, Moises A.
AU - Høgh, Julie
AU - Lauridsen, Emilie H.E.
AU - Hansen, Jesper B.
AU - Jensen, Jens Ulrik S.
AU - Perch, Michael
AU - Møller, Dina L.
AU - Pommergaard, Hans Christian
AU - Aagaard, Niels K.
AU - Davidsen, Jesper R.
AU - Lange, Peter
AU - Çolak, Yunus
AU - Afzal, Shoaib
AU - Nordestgaard, Børge G.
AU - Rasmussen, Allan
AU - Nielsen, Susanne D.
N1 - Publisher Copyright:
Copyright © 2024 Arentoft, Fialla, Krohn, Patursson, Thudium, Suarez-Zdunek, Høgh, Lauridsen, Hansen, Jensen, Perch, Møller, Pommergaard, Aagaard, Davidsen, Lange, Çolak, Afzal, Nordestgaard, Rasmussen and Nielsen.
PY - 2024
Y1 - 2024
N2 - Background: Fraction of exhaled nitric oxide with an expiratory flow of 50 mL/s (FENO50) is a biomarker of eosinophilic airway inflammation. Liver transplant recipients have an increased risk of pulmonary infections, but little is known about the burden of chronic pulmonary diseases in this group. We aimed to assess the prevalence of elevated FENO50 in liver transplant recipients and compare it to controls from the general population. Methods: FENO50 was measured in 271 liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients (DACOLT) study and 1,018 age- and sex-matched controls from The Copenhagen General Population Study (CGPS). Elevated FENO50 was defined as ≥25 or ≥50 parts per billion (ppb). The analyses were adjusted for known and suspected confounders. Results: The median age of the liver transplant recipients was 55 years (interquartile range (IQR) 46–64), and 58% were men. The liver transplant recipients had a higher median FENO50 than the controls [16 ppb (IQR 10–26) vs. 13 ppb (IQR 8–18.), p < 0.001]. Furthermore, the liver transplant recipients had a higher prevalence of elevated FENO50 (for FENO50 ≥25 ppb 27% vs. 11%, p < 0.001 and ≥50 ppb 4% vs. 2%, p = 0.02). The results were similar after adjusting for age, sex, smoking status, use of airway medication, and blood eosinophil counts [the adjusted odds ratio (OR) for FENO50 ≥25 ppb was 3.58 (95% CI: 2.50–5.15, p < 0.0001) and the adjusted OR for FENO50 ≥50 ppb was 3.14 (95% CI: 1.37–7.20, p = 0.007)]. Conclusion: The liver transplant recipients had elevated FENO50, implying increased eosinophilic airway inflammation. The clinical impact of this finding needs further investigation.
AB - Background: Fraction of exhaled nitric oxide with an expiratory flow of 50 mL/s (FENO50) is a biomarker of eosinophilic airway inflammation. Liver transplant recipients have an increased risk of pulmonary infections, but little is known about the burden of chronic pulmonary diseases in this group. We aimed to assess the prevalence of elevated FENO50 in liver transplant recipients and compare it to controls from the general population. Methods: FENO50 was measured in 271 liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients (DACOLT) study and 1,018 age- and sex-matched controls from The Copenhagen General Population Study (CGPS). Elevated FENO50 was defined as ≥25 or ≥50 parts per billion (ppb). The analyses were adjusted for known and suspected confounders. Results: The median age of the liver transplant recipients was 55 years (interquartile range (IQR) 46–64), and 58% were men. The liver transplant recipients had a higher median FENO50 than the controls [16 ppb (IQR 10–26) vs. 13 ppb (IQR 8–18.), p < 0.001]. Furthermore, the liver transplant recipients had a higher prevalence of elevated FENO50 (for FENO50 ≥25 ppb 27% vs. 11%, p < 0.001 and ≥50 ppb 4% vs. 2%, p = 0.02). The results were similar after adjusting for age, sex, smoking status, use of airway medication, and blood eosinophil counts [the adjusted odds ratio (OR) for FENO50 ≥25 ppb was 3.58 (95% CI: 2.50–5.15, p < 0.0001) and the adjusted OR for FENO50 ≥50 ppb was 3.14 (95% CI: 1.37–7.20, p = 0.007)]. Conclusion: The liver transplant recipients had elevated FENO50, implying increased eosinophilic airway inflammation. The clinical impact of this finding needs further investigation.
KW - comorbidity
KW - eosinophilic airway inflammation
KW - fraction of exhaled nitric oxide
KW - liver transplant recipient
KW - pulmonary disease
U2 - 10.3389/fimmu.2024.1330923
DO - 10.3389/fimmu.2024.1330923
M3 - Journal article
C2 - 38361926
AN - SCOPUS:85185114119
VL - 15
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 1330923
ER -